Oleo Technologies x Online Optimisers
Pre-Allwright Readiness Brief · 8 May 2026
01 / 12
For Richard Creagh and Shirley Creagh

Oleo Technologies
The Pre-Allwright Readiness Brief

Where Oleo stands today, what we found in the regulatory and competitive landscape, and the 90-day plan we would put in your hands the day MCAP expansion is on the table.

Tuesday 13 May 2026 By the way moment Cork · Dublin · Online
Scroll to begin ↓
02 / 12
Slide 2 · Where Oleo stands today

A small market with a defensible moat. Both true at once.

The MCAP register is small. Your operational footprint inside it is not. We read the gap as your wedge, not your weakness.

74
MCAP patients approved 2019 to 2026
5 years operational. Roughly 15 newly approved patients per year. Ministerial answer March 2026.
22
Active prescribing consultants
Specialist register only. GPs cannot initiate. About 4 prescriptions per consultant per year. Cultural and procedural drag, not a demand signal.
70%
Prescribed-once-stopped indicator
Estimated patient drop-off after the first prescription cycle. The pathway is harder than it should be. OleoCare is the data layer that fixes that.

What the surface numbers do not tell you. What you actually own.

  • Bedrocan import licence. Three-year regulatory grind, single-supplier moat for ministerial-licence patients. Not commodity.
  • Panacea vaporiser device. Already photographed, pitch-ready, sits inside the supply chain.
  • OleoCare app live in market. The only Irish-built patient-and-prescriber data layer. RWE-grade if positioned that way.
  • truMED parallel rails. Richard's US digital health platform. Reusable architecture, not a brand collision.
  • Celadon Pharmaceuticals contacts. UK-listed CBM operator network. Quietly held, not yet activated.
  • Olio.com option. Your post-Allwright consumer brand-extension lever for the day the door opens further.
Source: HPRA, Department of Health, Ministerial answer March 2026, Prohibition Partners 2025. The 70 percent prescribed-once-stopped figure is an inference flagged for Oleo confirmation.
03 / 12
Slide 3 · The competitor set

Four threats, four different shapes.

Most of these are not Irish. None of them have your stack. The question is what they do when Allwright lands.

Curaleaf Clinic BelfastUK / cross-border NI
Active threat
40,000 plus on UK Medical Cannabis Registry. Belfast clinic prescribes to NI residents. ROI patients already travelling north.
Oleo read. They will not own the Allwright explainer in IE. They do not have OleoCare or Bedrocan-direct ROI rails. Beat them on Irish-incorporated authority.
Sapphire Medical UKUK private
Adjacent
Vertically integrated import-prescribe-dispense. UK Medical Cannabis Registry administrator. Cannabis Clinic of the Year 2024.
Oleo read. Strong RWE pedigree. They will publish UK-Irish-applicable explainers. Oleo answers with OleoCare as the only Irish-built RWE source.
Tilray Medical IECanadian / Irish-facing
Direct rival
tilraymedical.ie live. THC10:CBD10 oral solution relaunched 2022. Government reimbursement in place. Closest to Oleo on Irish presence.
Oleo read. Distribution-only Irish posture, no founder voice, no app, no Cork office. Their playbook is volume content. Yours is entity authority.
Bedrocan-direct alt routesEU / parallel
Structural risk
Single-supplier dependency for ROI ministerial-licence patients. Magistral pharmacy bottleneck in NL. Two steps in another jurisdiction.
Oleo read. Not a competitor today. The risk is supply, not market share. Allwright expansion makes Bedrocan continuity the moat, or the chokepoint.
Source: UK Medical Cannabis Registry 2025, Curaleaf and Sapphire public filings, Tilray IR MCAP relaunch announcement, Bedrocan supply chain documentation. Cross-border NI flow figures are inference-flagged.
04 / 12
Slide 4 · AI ranking probe outcome

Zero citation likelihood today on the queries that matter most.

We probed 40 buyer- and prescriber-intent queries across four engines. On the queries that route Allwright-curious clinicians, patients, and policy researchers, Oleo is invisible. The slot is empty. Whoever fills it first holds it.

ChatGPT
0%
0 / 40 cells. "MCAP eligibility Ireland" routes to gov.ie and Business of Cannabis. "Bedrocan in Ireland" never names Oleo.
Perplexity
3%
1 / 40 cells. One brand-direct query surfaces oleo.ie. Every regulatory and clinical query routes to HPRA, gov.ie, Tilray.
Google AIO
0%
0 / 40 cells. Prescriber-pathway queries route to HSE and HPRA. No schema, no FAQ markup, no product-level entity surfaced.
Claude / Gemini
0%
0 / 40 cells. Safety filters cap clinical cannabis queries. Founder credibility content would unlock entity surfacing here.

Per Rule 05 we frame this as increased likelihood of citation, not guaranteed placement. The probabilistic frame holds. The reason Oleo can move the number is that nobody else has invested in entity authority for these queries. The slot is empty. Pre-Allwright is the perishable window. Post-Allwright the auction crowds with UK clinic content.

Sample queries probed include: MCAP eligibility Ireland, medical cannabis prescribers Dublin, Bedrocan in Ireland, what is MCAP, Allwright Review explained, medical cannabis app Ireland, Section 56 dispensing pharmacy cannabis. Full 40-query sample list available in deep-audit appendix.
05 / 12
Slide 5 · Strategy fan

Six concurrent rails. Each defensible on its own.

Not a single SEO play. Six rails that compound into entity authority, regulatory readiness, and operational efficiency at the same time.

01

Organic content engine

MCAP, Bedrocan-in-Ireland, Allwright explainer, prescriber pathway. Twelve priority queries from the market dive. HPRA-cite-eligible authority sources only.
02

ASAI-compliant patient navigator

Public-facing hub that respects ASAI 7th edition. No direct-to-public product advertising. Pathway, eligibility, what to ask your consultant.
03

Prescriber portal

Gated MCAP-prescriber verification. Product information behind the gate. Batch availability, COA on request, direct supply ordering.
04

Pharmacy network rail

Section 56 dispensing pharmacy onboarding pack. Schedule 1 controlled drug handling brief. Stocking economics for post-Allwright readiness.
05

Allwright lobbying support

Submission drafting, OleoCare RWE positioning, ROI cross-border evidence. Position Oleo as a regulatory-engaged operator, not a passive supplier.
06

truMED architecture port

Reuse Richard's US digital health platform patterns where appropriate. Patient-prescriber data plumbing without crossing the brand walls.
Per Rule 05 and STYLE-GUIDE compliance language: every rail is built within ASAI 7th edition limits. Public-facing surfaces never advertise prescription-only products by name. The brand wall to TheBudtender is absolute on every rail.
06 / 12
Slide 6 · The 90-day plan

Three pillars. Twelve weeks. Acceptance criteria, not promises.

Same six rails sequenced into three pillars. We deliver pillars, you keep the work. If a milestone slips we say so.

Pillar 1Regulatory readiness
Submission pack, OleoCare RWE positioning, HPRA correspondence templates
Pillar 222-consultant reactivation
Prescriber portal v1, prescriber-pack mailshot, pharmacy network onboarding
Pillar 3AI ranking foundation
Schema, twelve priority articles, founder credibility content, baseline plus 90-day re-probe

Week 4 acceptance

  • Allwright submission first draft circulated for Richard review
  • Prescriber portal v1 live behind MCAP-prescriber gate
  • First six articles published with Article and FAQ schema
  • 22-consultant prescriber pack mailed with read tracking live

Week 12 acceptance

  • Allwright submission final version delivered
  • Twelve priority articles live, AI citation re-probed
  • Prescriber portal usage on the dashboard, batch availability live
  • Pharmacy network onboarding pack distributed to Section 56 list
07 / 12
Slide 7 · KPI dashboard mockup

Four numbers that move every week.

Built into a private Oleo dashboard, refreshed weekly. Not vanity metrics. Each one ties to the regulatory and commercial reality of the programme.

Consultant reactivations
0 / 22
Target Wk 12: 8 / 22 active
Prescriber-portal inquiries
0
Target Wk 12: 30 verified
AI citation count
1 / 160
Target Wk 12: 20 to 30 cells
OleoCare onboardings
live
Target Wk 12: + 18 enrolments

Why these four, not ten

A 74-patient programme does not need a ten-metric dashboard. It needs visibility on the four levers that move the next prescription, the next consultant, the next regulatory data point. Everything else is noise until volume justifies it.

Reading the column above

"Now" reflects the public-record baseline at 2026-05-08. "Target Wk 12" assumes Phase 1 retainer kicks off Mon 19 May. Every figure recalibrated at Week 4 and Week 12 with re-probed AI citation and live OleoCare data.

Dashboard mockup. Hosted private to Richard, Shirley, John Coffey. No patient-identifiable data. OleoCare onboarding metric is volume only, never patient-level.
08 / 12
Slide 8 · Patient or prescriber bot

The intake layer. ASAI-compliant by design.

A two-route bot. Patient enquiries route to the public navigator and the eligibility check. Prescribers route to gated portal verification and OleoCare onboarding.

Oleo Intake · v0 demo Static mockup
Welcome. Are you a patient, a healthcare professional, or a pharmacy?
Patient Healthcare professional Pharmacy
Healthcare professional
Are you registered on the Medical Council Specialist Register and prescribing under the Medical Cannabis Access Programme, or considering it?
MCAP-registered prescriber Considering MCAP enrolment
MCAP-registered prescriber
We will route you to the prescriber portal to verify and access product information, batch availability, and OleoCare onboarding for your patient.

What this layer does

  • Patient route: ASAI-compliant navigator, MCAP eligibility check, "speak to your healthcare professional" pathway. No product names, no efficacy claims.
  • Prescriber route: Specialist register self-attestation, then portal sign-up. Product information lives behind the gate, never on the public surface.
  • Pharmacy route: Section 56 dispensing onboarding, controlled drug handling brief, batch supply request workflow.
  • Pharmacovigilance hook: Adverse event reporting handoff to OleoCare or HPRA, depending on context.

What it is not

Not a sales bot. Not a triage tool. Not a clinical decision aid. The category does not allow it and the brand should not want it. The bot is a clean intake layer that respects the regulatory frame end to end.

Demo build sits behind a private password. No public deployment until ASAI compliance review and Richard sign-off. The static mockup is for direction only.
09 / 12
Slide 9 · Investment

The shape of the investment.

Anchored against UK private clinic SEO budgets, with an Irish regulatory premium reflecting the complexity of MCAP, ASAI, HPRA, and the prescriber-portal stack.

EUR4 to 6K / mo range
Final tier locked Tue 27 May after discovery deepens
Phase 1 of a 12-month plan

Where comparable budgets sit

  • Curaleaf Clinic UK: GBP 15 to 25k per month. Full agency, in-house content, regulatory PR.
  • Sapphire Medical / RWE-led UK clinics: GBP 10 to 18k per month. Heavy schema and clinical content layer.
  • Releaf UK platform: GBP 8 to 14k per month. Tech-led, GBP 2m platform launched 2025.
  • Mamedica independent UK clinic: GBP 6 to 10k per month. Mid-tier independent operator.
  • Tilray Medical IE distribution-only: estimated GBP 3 to 5k per month. Volume content, no Irish founder voice.

Source inferred from on-site signal, agency disclosures, and 2025 platform launches. UK private clinic competitor budgets per market dive section 5.

Why the Irish regulatory premium

The UK numbers above buy SEO and content for an open prescription-cannabis market. Oleo's retainer also has to navigate ASAI 7th edition, HPRA correspondence, MCAP submission drafting, prescriber-portal compliance, and Schedule 1 controlled drug handling. EUR 4 to 6k per month buys the same quality of work plus the regulatory rails the UK operators do not need.

No performance guarantee. Honest reason why.

Cannabis SEO timelines and Allwright recommendations are both probabilistic. A 25-year medtech operator reads a guarantee as desperation, not confidence. We replace the guarantee with milestone-gated scope: specific deliverables tied to specific weeks, with the AI ranking re-probe baked into Week 4 and Week 12.

10 / 12
Slide 10 · Why retainer not handoff

The structural call.

Fair question and we want to answer it before you ask. The Oleo work is regulatory, technical, and compounding. Not a six-week project.

Hand-off to John alone

  • One person doing tasks, no toolchain underneath
  • No DataForSEO, Firecrawl, Claude Code, ranking dashboards
  • QA bottlenecked on John's day-job hours at Oleo
  • Strategy is whatever John has time to think about that week
  • Compounding work breaks: AI ranking and regulatory readiness are systems, not checklists

Embedded retainer (recommended)

  • John is your day-to-day single point of contact
  • OO retains the toolchain (DataForSEO, Firecrawl, Claude Code, ranking dashboards)
  • Donal owns strategy and weekly QA across the work
  • John gets credit on your side and a milestone bonus tied to your retention plus prescriber and patient targets
  • The work compounds: 90 days builds an asset, not a deliverable

John Coffey · your relationship lead

Operations and marketing background, taking a production role at Oleo from 2 June. Same person you have been talking to for the last month. Bonus aligned with your retention and your prescriber and patient targets, not ours.

11 / 12
Slide 11 · The wedge close

Day-1 of Allwright Readiness Package.

Free. Yours to keep. Ships within 7 days of green light, whether you retain us or not.

His to keep · no obligation

What lands in Richard's inbox by Wed 14 May plus 7

Five artefacts that compound regardless of what you do next. Built whether or not the retainer happens. The point is to leave you better positioned for Allwright than you were last week.

  • Allwright submission scaffold v1. Section structure, evidence-base map, OleoCare RWE positioning, ROI cross-border argument.
  • 22-consultant prescriber pack draft. One-page MCAP enrolment summary, current product list with batch availability, direct line to clinical support copy.
  • AI ranking baseline report. The 0 / 160 figure with 40 sample queries, four engines, mapped to publish targets.
  • Twelve-query content map. Priority list with HPRA-cite-eligible source pairing for each.
  • Pharmacy network shortlist. Section 56 dispensing pharmacies in IE with controlled drug handling capability, ranked by post-Allwright stocking readiness.

Why we ship it free. Two reasons. One: a 25-year medtech operator does not need to be sold to. Two: if Allwright lands and you have not started, the cost of that delay is bigger than any retainer fee. The package gets Oleo moving regardless. If we earn the retainer, we earn it on the work.

12 / 12
Slide 12 · The defined finish

Regroup Tuesday 27 May.
Sharper plan, locked tier, defined start.

Wed 14 May
Day-1 of Allwright Readiness Package shipped to Richard
Tue 20 May
Internal review with Richard, Shirley, John
Tue 27 May
Regroup call: tier locked, start date defined
Mon 2 June
Phase 1 begins, John takes production role

What we need from Oleo before Tue 27 May

  • Confirmation of 2026 patient and ministerial-licence count
  • Read-only access to oleo.ie analytics and Search Console
  • Pharmacy stocking reality check: zero stocked, or partial?
  • Allwright submission deadline confirmation if known
  • 30-min onboarding with Shirley on OleoCare data model

What we are not asking for today

  • A signed retainer
  • A budget commitment
  • Access to anything we cannot demonstrate need for
  • A decision before you have read the package

If you want to think on it, take the week. We do not chase. The plan does not change if you start in three weeks instead of two.

Dig deeper, your own time

Oleo deep audit Strategy hub Constellation orb Market dive v1 IE / UK competitor matrix Brand kit
Cannabis-based medicinal products supplied by Oleo Technologies are prescription-only and available only via prescription from an MCAP-registered prescriber. This document is a private discovery brief for Oleo Technologies. It does not constitute medical advice, marketing of prescription-only medicines under ASAI 7th edition, or a public-facing communication.